Fuji Pharma Co Ltd
TSE:4554
Fuji Pharma Co Ltd
TSE:4554
Price:
1 529 JPY
0.72%
Market Closed
Updated:
May 16, 2024
Fuji Pharma Co Ltd
Income from Continuing Operations
|
Fuji Pharma Co Ltd
Income from Continuing Operations Peer Comparison
Comparables:
4502
4568
4578
4519
4503
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fuji Pharma Co Ltd
TSE:4554
|
Income from Continuing Operations
¥5.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Income from Continuing Operations
¥178.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
10%
|
CAGR 10-Years
2%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Income from Continuing Operations
¥186.6B
|
CAGR 3-Years
38%
|
CAGR 5-Years
23%
|
CAGR 10-Years
6%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Income from Continuing Operations
¥141.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Income from Continuing Operations
¥325.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
28%
|
CAGR 10-Years
20%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Income from Continuing Operations
¥37.3B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-9%
|
See Also
What is Fuji Pharma Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
5.1B
JPY
5.1B
JPY
Based on the financial report for Dec 31, 2023, Fuji Pharma Co Ltd's Income from Continuing Operations amounts to 5.1B JPY.
What is Fuji Pharma Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
10%
10%
Over the last year, the Income from Continuing Operations growth was 88%. The average annual Income from Continuing Operations growth rates for Fuji Pharma Co Ltd have been 24% over the past three years , 10% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
